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Objective and methods: To evaluate the immune-modulator effect of chondroitin sulfate (CS) by means of
the review of the literature.
Results: Inﬂammatory reactions are primarily originated by infectious agents, immune reactions and by
sterile tissue lesions that activate membrane receptors by means of pathogen-associated molecular
patterns, tissue breakdown products and cytokines. The activation of membrane receptors triggers the
phosphorylation of mitogen activated protein kinases and of the nuclear factor kB (NF-kB). The binding of
NF-kB to the promoter of target genes enhances the expression of pro-inﬂammatory cytokines, inducible
nitric oxide synthase, cyclooxygenase 2, phospholipase A2, and matrix metalloproteases, proteins that
contribute to tissue damage and to the inﬂammatory reaction. The activation of NF-kB has a key role in
the immune homeostasis and the inﬂammatory response and therefore, in the pathogenesis of numerous
diseases. Chondroitin sulfate (CS) is able to diminish NF-kB activation and nuclear translocation in
chondrocytes and synovial membrane, effects that may explain the beneﬁts of CS in osteoarthritis. In
addition, systemic CS reduces NF-kB nuclear translocation in macrophages and hepatocytes, raising the
hypothesis that CS might be of beneﬁt to treat other diseases with a strong inﬂammatory component.
There is preliminary evidence in humans that CS improves moderate to severe psoriasis. Moreover,
experimental and clinical data suggest that CS might be a useful therapeutic agent in diseases such as
inﬂammatory bowel diseases, atherosclerosis, Parkinson’s and Alzheimer’s diseases, multiple sclerosis,
amyotrophic lateral sclerosis, rheumatoid arthritis and systemic lupus erythematosus.
Discussion: These results urge for double blinded placebo-controlled trials to conﬁrm the utility of CS in
diseases with immune and inﬂammatory components.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Inﬂammation
The deployment of defensive responses of the organism caused
by infectious pathogens or by sterile tissue damage characterizes
any inﬂammatory reaction (Fig. 1). Infections caused by bacteria,
protozoa, fungi, and viruses activate the pattern-recognition
receptors (PRRs) in immune cells by means of cell-membrane
molecules and/or of lipopolysaccharides (LPS). The most frequently
activated membrane PRRs are toll-like receptors 1e13 (TLR1e13),
scavenger receptors such as CD36, and complement receptors.
Pathogen-associated molecular patterns (PAMPs) and LPS can also
activate a cytoplasmic PRR, the nucleotide-oligomerization domain
(NOD-like receptor e NLR)1e3.
Following a sterile tissue lesion, heat shock proteins 60 and 70




s Research Society International. Psurfactant protein A, and breakdown products of tissue matrix
(ﬁbronectin, hyaluronic acid, and heparan sulfate) are released in
the nearby interstitial space. These endogenous compounds will
activate PRRs but may also activate other receptors in immune and
other tissue cells.4 For instance, ﬁbronectin fragments bind to a5b1-
integrin and CD44, hyaluronic acid fragments stimulate CD44 and
TLRs, and heparan sulfate proteoglycans and ﬁbrinogen activate
TLRs5,6. It is noteworthy that Hsps may penetrate into the blood-
stream and through cell-surface receptors, such as TLRs and scav-
enger receptor CD36, produce an effect at distant sites in the body7.
In immune cells and cells in any type of tissue, the activation of
PRRs, a5b1-integrin, and CD44 by PAMPs, LPS, Hsps, and endoge-
nous breakdown products will lead to the phosphorylation and
activation of extracellular signal-regulated kinase 1/2 (ERK1/2), p38
mitogen activated protein kinase (p38MAPK), and c-Jun NH2-
terminal kinase (JNK)8,9. These kinases phosphorylate the IkB
kinase (IKK) which will phosphorylate and inactivate the inhibitor
kBa (IkBa) that is forming a complex with the p65/p50 heterodimer
or nuclear factor-kB (NF-kB) in the cytosol; as a consequence of IkBa
inactivation, NF-kB is released and initiates the translocation to theublished by Elsevier Ltd. All rights reserved.
Fig. 1. In immune cells, bacteria, protozoa, fungi and viruses activate the PRRs by means of PAMPs and/or LPS, and as a consequence, activate the ERK1/2, p38MAPK, and JNK. These
kinases stimulate the nuclear translocation of the p65/p50 heterodimer or NF-kB and binding to target gene, followed by the increase of expression of pro- and anti-inﬂammatory
cytokines, NOS2, COX-2, PLA2 and MMPs, factors that will perpetrate the inﬂammatory reaction and the inﬂammatory disease. On the other hand, a sterile tissue lesion will release
Hsps, Grps, ﬁbrinogen, surfactant protein A and breakdown products of tissue matrix (ﬁbronectin, hyaluronic acid, and heparan sulfate), compounds that will activate PRRs in
immune cells and scavenger receptors in cells of any tissue to further activate the nuclear translocation of NF-kB.
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promoters/enhancers of hundreds of target genes, in such way that
NF-kB regulates the transcription of genes that are involved in
inﬂammation, immunity, apoptosis, cell proliferation and differ-
entiation. As a result of NF-kB binding to target genes, the
expression of many proteins increases, such as pro- and anti-
inﬂammatory cytokines, e.g., interleukin-1b (IL-1b), interleukin-6
(IL-6), tumor necrosis factor-a (TNF-a), and enzymes, such as
inducible nitric oxide synthase (NOS2), cyclooxygenase 2 (COX-2),
phospholipase A2 (PLA2), matrix metalloproteases (MMPs), e.g.,
MMP-3, MMP-9, MMP-13, etc., all factors that will perpetrate the
inﬂammatory reaction3,12.
There is evidence that the activation of NF-kB has a causative
role in the pathogenesis of numerous diseases, such as inﬂamma-
tory bowel disease13, gastritis14, rheumatoid arthritis15, psoriasis16,
atherosclerosis17, Alzheimer’s disease18, Parkinson’s disease19,
asthma, acute respiratory distress syndrome20, sepsis and systemic
inﬂammatory response syndrome21, cancer22, systemic lupus
erythematosus15, amyotrophic lateral sclerosis, multiple sclerosis23,
and type I diabetes18,24. The key role of NF-kB in inﬂammatory
responses and immune homeostasis explains the interest of
compounds targeting any step leading to its nuclear translocation
for the treatment of diseases with an inﬂammatory component.
It is noteworthy that the evolution and prognosis of the above
listed diseases, where nuclear translocation of NF-kB is a funda-
mental event, is associated with blood biomarkers of inﬂammation,
primarily IL-6 and C-reactive protein (CRP). For instance, plasma
concentrations of IL-6 and CRP are closely associated to the
evolution and severity of inﬂammatory bowel diseases25,26, psori-
asis27, atherosclerosis and myocardial infarction28,29, Parkinson’s
and Alzheimer’s diseases30,31, amyotrophic lateral sclerosis32,
cancer33,34, and diabetes35. In some instances, such as cancer, its
relationship with serum concentrations of biomarkers of inﬂam-
mation is close enough to formulate the hypothesis that NF-kB
system is part of the pathophysiology of cancer formation.Therefore, it has been proposed that anti-inﬂammatory agents that
suppress NF-kB or NF-kB-regulated products should be potentially
helpful in both the prevention and treatment of cancer36.
Modulation of inﬂammation by chondroitin sulfate
Osteoarthritis
Osteoarthritis is characterized by focal areas of loss of joint
cartilage, with varying degrees of osteophyte formation, sub-
chondral bone change and synovitis. The pathophysiology of
osteoarthrosis appears to be associated to multiple microtraumas
to the joint cartilage and formation of extracellular matrix frag-
ments (EMFs)37. These fragments bind to a5b1 integrin receptor,
CD44 and TLRs on the chondrocytes and on the macrophages of the
synovial membrane where they activate ERK1/2, p38MAPK and
JNK, and subsequently trigger the nuclear translocation of the
activator protein-1 (AP-1) and NF-kBwhich enhance the expression
of MMPs, IL-1b, TNF-a, PLA2, COX-2 and NOS2 (Fig. 2)38. This
chronic inﬂammatory reaction will be at the origin of the synovitis
and the damage and loss of cartilage39,40.
In vitro, in chondrocytes, IL-1b activates ERK1/2, p38MAPK, and
JNK, and induces the nuclear translocation of NF-kB and AP-141.
Using the chondrocyte stimulated by IL-1b as experimental model, it
has been shown that bovine chondroitin sulfate (CS) diminishes IL-
1b-induced NF-kB nuclear translocation. In addition, CS inhibits
IL-1b-induced p38MAPK and ERK1/2 phosphorylation.42 Moreover,
the disaccharides Ddi-4S and Ddi-6S of CS also reduce IL-1b-induced
NF-kB nuclear translocation in the chondrocyte39. It is unclear how
CS elicits its effects. It has been shown that CS is internalized in the
cell via the hyaluronan receptor for endocytosis (HARE)43, and other
scavenger receptors such as CD3644 and CD4445. The mechanism by
which CS reduces p38MAPK and ERK1/2 phosphorylation and NF-kB
nuclear translocation remains unclear but it has been reported that
inhibition of hyaluronan binding to CD44 by CS diminishes ERK1/2
Fig. 2. CS, by reducing the phosphorylation of ERK1/2 and p38MAPK, diminishes the nuclear translocation of NF-kB triggered by Hsps, Grps, ﬁbronectin (Fn-f) and EMFs,
pro-inﬂammatory cytokines, IL-1b and TNF-a, PAMPs and LPS. As a consequence, CS reduces the expression of pro-inﬂammatory cytokines, NOS2, COX-2, PLA2 and MMPs, and
diminishes the inﬂammatory reaction. This mechanism of action may explain the effect of CS in diseases with a strong inﬂammatory component. Solid large arrow indicates solid
clinical evidence, solid narrow arrow denotes preliminary clinical evidence, and broken arrow indicates experimental and/or rather preliminary clinical evidence.
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is redox-sensitive, once internalized by HARE, the antioxidant
activity of CS may have contributed to these effects47.
There is strong evidence that nuclear translocation of NF-kB is
pivotal to the presentation andmaintenance of synovitis. Following
the in vitro transfection of the inhibitory subunit IkBa in synovio-
cytes, IL-1b-induced NF-kB nuclear translocation is inhibited, as is
the production of IL-6, of chemokines monocyte chemoattractant
protein-1 (MCP-1) and RANTES, of p75 soluble TNF-a receptor, of
MMP-1, MMP-3, MMP-13, and of the expression of aggrecanase-1
or ADAMTS448. On the other hand, in the rat adjuvant arthritis
model, speciﬁc inhibition of IKK-b-mediated NF-kB activation
locally in the inﬂamed joint, using a NEMO-binding domain (NBD)
peptide, reduces synovial inﬂammation49.
CS reduces the signs of synovitis in animal models as well as in
humans. In DBA/1J mice with a type II collagen-induced arthritis
and treated for 9 weeks with various dosages of CS, the inﬁltration
of inﬂammatory cells, granulated tissue formation and proliferation
of synovial lining cells, as well as swelling, were partially prevented
by treatment with 1000 mg/kg/day of CS orally for 63 days50. In
patients with knee OA, bovine CS diminished the number of
patients with signs of synovitis from 90 of 307 at baseline to 38 at
the end of 24 weeks of treatment51.
Because of the high sulfate and carboxyl group content, CS has
strong negative charges, property that allows CS to interact with
a wide range of proteins, including receptors, enzymes, cytokines,
chemokines, lipoproteins, and adhesion molecules, and confers CS
with its antioxidant properties. However, there is no information
about the speciﬁc role of CS disaccharides, sulfated and non-
sulfated, when CS is administered systemically. In vitro, CS disac-
charides inhibit NF-kB nuclear translocation induced by IL-1b39, the
Ddi-4,6S being more potent than the Ddi-6S and the Ddi-4S. In the
experimental autoimmune encephalomyelitis, Ddi-6S promotes
recovery and neuronal survival, effect associated with an inhibition
of NF-kB nuclear translocation52. These reports suggest that CS
disaccharides show pharmacological activity but unfortunately,
there is no information about the efﬁcacy and potency of the
disaccharides as a function of their content in sulfate.Based on these reports, wemay speculate that the effect of CS on
the symptomatology and evolution of osteoarthritis in
patients53e55 is associated to the inhibition of NF-kB nuclear
translocation in chondrocytes, synovial macrophages and syno-
viocytes. On the other hand, using the combined in vivo model of
chronic arthritis and atherosclerosis, intraperitoneal bovine CS
diminishes NF-kB nuclear translocation in peripheral blood
mononuclear cells56. Unpublished results from our laboratory show
that in vivo orally administered CS abrogates the hepatic nuclear
translocation of NF-kB induced by an aseptic inﬂammatory reac-
tion. Altogether, these reports suggest that in vivo CS may reduce
NF-kB nuclear translocation in many tissues.
Is it noteworthy that as a consequence of the inhibition of NF-kB
nuclear translocation by CS, biomarkers of inﬂammation are
reduced in vivo. In rabbits with the combined model of chronic
arthritis and atherosclerosis, intraperitoneal administration of CS
reduces serum concentrations of IL-6 and CRP, and diminishes the
production of the chemokine MCP-1 by blood mononuclear cells56.
The effect of CS on NF-kB and biomarkers of inﬂammation, CRP and
IL-6, further support the hypothesis that CS might be of therapeutic
value for diseases associated with an inﬂammatory reaction.
Psoriasis
Nuclear expression of NF-kB is detected in 66% of psoriatic
lesions and over-expressed in psoriasis compared with normal
skin57. Compared with non-lesional psoriatic skin, in lesional
psoriatic skin, NF-kB DNA binding to the p53kB site is decreased,
whereas NF-kB binding to the proinﬂammatory IL-8 kB site is
increased58. In a hospital based caseecontrol study, including 519
patients with psoriasis vulgaris and 541 matched controls who
were genotyped for NFkB1 (encodes for p50 protein) poly-
morphisms, it was observed that NFkB1 wild-type genotype was
associated to an increased risk for psoriasis vulgaris; the association
was stronger in the subgroups of onset age 40 years, Psoriasis Area
and Severity Index (PASI) score around 20, and male patients59.
Further supporting the role of NF-kB in the incidence/severity of
psoriasis, effective treatment with etanercept, a recombinant
M. Vallières, P. du Souich / Osteoarthritis and Cartilage 18 (2010) S1eS6S4human TNF receptor fusion protein, produced a signiﬁcant down-
regulation of phosphorylated NF-kB, reduction that correlated with
the improvement of skin histology and clinical outcomes60.
In order to assess the efﬁcacy of CS for the treatment of psoriasis,
in an open non-controlled trial, 11 patients with knee OA and long-
standing, moderate-to-severe psoriasis resistant to conventional
therapy, received 800 mg/day of bovine CS for 2 months. The
results showed that swelling, redness, ﬂaking and itching of the
skin was diminished, and hydration and softening of the skin was
enhanced with a reduction of scaling; in addition, epidermal
thickness was decreased, the number of keratinocytes were
reduced and the severity of psoriasis activity diminished61. These
results suggest that bovine CS might be a helpful agent to treat
selected patients with moderate-to-severe psoriasis.Inﬂammatory bowel disease
An eventual beneﬁt of CS for the treatment of inﬂammatory
bowel diseases has been explored. Using themurine dextran sulfate
sodium-induced colitis (DSS-IC) model, it was shown in vivo that
oral CS reduces the bloody stools as well as erosions, and impedes
the increase of white blood cells more effectively than 5-amino-
salicylic acid62. On the other hand, with the same DSS-IC model, it
was shown that oral glucosamine improved the clinical symptoms
and suppressed colonic inﬂammation and tissue injury; moreover,
glucosamine inhibited the activation of intestinal epithelial cells, as
demonstrated by a diminished nuclear translocation of NF-kB in the
intestinal mucosa63. The experimental evidence reviewed support
the hypothesis that CS might reduce the incidence and severity of
relapse of inﬂammatory bowel diseases in humans.Atherosclerosis
The incidence and progression of atherosclerosis and subse-
quent cardiovascular complications, e.g., myocardial infarction and
stroke, are closely associated to inﬂammation. There is strong
evidence that NF-kB is a pivotal transcription factor in the heart
and cardiovascular system64, and that pro-inﬂammatory cytokines
IL-1b and TNF-a play a crucial role in the disruption of macro-
vascular and microvascular circulation both in vivo and in vitro65
Moreover, the biomarkers CRP and IL-6 are highly predictive of
cardiovascular events66. The beneﬁcial effect of acetylsalicylic acid
on cardiovascular events has been in part explained by a reduction
of NF-kB nuclear translocation67. There is experimental56,68 and
clinical data69,70 suggesting that CS might be of utility to prevent
or diminish the incidence of atherosclerosis and its complications.
Additional placebo-controlled trials are required to demonstrate
the usefulness of CS for the treatment of atherosclerotic diseases.
In conclusion, the activation of NF-kB is pivotal to immune
homeostasis and the inﬂammatory response and therefore, in the
pathogenesis of numerous diseases. The beneﬁts of CS in osteoar-
thritis may be explained by reduction of NF-kB nuclear trans-
location in chondrocytes and synovial membrane. In addition,
systemic CS reduces NF-kB nuclear translocation in macrophages
and hepatocytes, raising the hypothesis that CS might be of beneﬁt
to treat other diseases with a strong inﬂammatory component.
Supporting such statement, there is evidence in humans that CS
improves moderate to severe psoriasis.
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